Search
Krystal Biotech Inc
KRYSAdd to Watchlist
347.630USD
+7.420+2.18%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
10.25BMarket Cap
44.88P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.18%
5 Days
+1.75%
1 Month
+16.09%
6 Months
+38.34%
Year to Date
+41.00%
1 Year
+141.96%
Key Figures
343.590Open
353.890High
378.47KVolume
44.88P/E TTM
33.16P/E Dynamic
--Dividend TTM
1.29%Turnover Ratio
340.210Prev. Close
343.590Low
91.14MTurnover
114.77P/E Static
8.02P/B
0.00%Div Yield TTM
18.21%ROA
319.48052wk High
0.81Volume Ratio
89.16MNet Profit
29.44MShares
7.7464EPS TTM
0.52Beta
19.90%ROE
123.03452wk Low
3.03%Amplitude
94.57%Gross Margin
10.25BMarket Cap
5.35Reward/Risk
2.32%Risk Rate
TradingKey Stock Score of Krystal Biotech Inc
Currency: USD Updated: 2026-06-24Key Insights
Krystal Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 2 out of 388 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 328.20.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Krystal Biotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Krystal Biotech Inc Highlights
StrengthsRisks
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 667.53% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 389.13M.
Fairly Valued
The company’s latest PE is 44.88, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 32.60M shares, increasing 4.36% quarter-over-quarter.
Held by Ray Dalio
Star Investor Ray Dalio holds 39.07K shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
328.200
Target Price
-5.71%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Krystal Biotech Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Krystal Biotech Inc Info
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Ticker SymbolKRYS
CompanyKrystal Biotech Inc
CEOKrishnan (Krish S)
Websitehttps://www.krystalbio.com/
Related Instruments
+0.90%
+0.82%
+0.08%
-0.14%
+0.88%
+0.83%
+1.27%
-0.02%
+0.09%
-2.71%
+1.45%
-0.89%
-1.86%
-0.65%
+0.41%
0.00%
+0.87%
+1.80%
-0.11%
-0.76%Popular Instruments
52005.400
+33.700 (+0.07%)
29866.700
+72.500 (+0.24%)
7419.800
+9.400 (+0.13%)
15808.000
+271.000 (+1.74%)
72388.000
+1431.000 (+2.02%)
6260.200
+32.000 (+0.51%)
69.494
-0.265 (-0.38%)
293.080
-1.220 (-0.41%)
199.000
-1.040 (-0.52%)
3983.510
-15.230 (-0.38%)
FAQs
What is the current price of Krystal Biotech Inc (KRYS)?
The current price of Krystal Biotech Inc (KRYS) is 347.63.
What is the symbol of Krystal Biotech Inc?
The ticker symbol of Krystal Biotech Inc is KRYS.
What is the 52-week high of Krystal Biotech Inc?
The 52-week high of Krystal Biotech Inc is 319.48.
What is the 52-week low of Krystal Biotech Inc?
The 52-week low of Krystal Biotech Inc is 123.03.
What is the market capitalization of Krystal Biotech Inc?
The market capitalization of Krystal Biotech Inc is 10.23B.
Is Krystal Biotech Inc (KRYS) currently rated as Buy, Hold, or Sell?
According to analysts, Krystal Biotech Inc (KRYS) has an overall rating of Buy, with a price target of 328.20.
What is the Earnings Per Share (EPS TTM) of Krystal Biotech Inc (KRYS)?
The Earnings Per Share (EPS TTM) of Krystal Biotech Inc (KRYS) is 7.08.
